highperformr logo

Sarepta Therapeutics's Overview

Total employees1522
HeadquartersCambridge
Founded

Sarepta Therapeutics is a global biotechnology company at the forefront of precision genetic medicine, dedicated to engineering and delivering life-changing therapies for individuals affected by rare, devastating diseases. With a primary focus on Duchenne muscular dystrophy (DMD), Sarepta is advancing a robust and diverse pipeline of RNA-targeted therapeutics, gene therapy, and gene editing programs. The company's mission is driven by a commitment to patients, scientific innovation, and a relentless pursuit of treatments for diseases with limited or no therapeutic options. Sarepta strives to make a profound impact on the lives of patients and their families through groundbreaking science and a deep understanding of the patient journey.

Where is Sarepta Therapeutics's Headquarters?

Sarepta Therapeutics officeSarepta Therapeutics officeSarepta Therapeutics officeSarepta Therapeutics office
*Images sourced via web search. Rights belong to original owners

HQ Function

The Cambridge headquarters serves as the central command for Sarepta's global operations, including corporate leadership, strategic decision-making, research and development oversight, and administrative functions.

Notable Features:

Located in a modern facility, the headquarters is designed to foster innovation and collaboration. It likely includes advanced laboratory spaces, open-plan offices, and meeting areas equipped for a dynamic biotech environment.

Work Culture:

Sarepta's Cambridge HQ fosters a mission-driven and patient-focused work culture. Employees are often described as passionate, dedicated, and collaborative, working in a fast-paced environment to advance science and bring therapies to patients in need.

HQ Significance:

Its Kendall Square location provides Sarepta with unparalleled access to a rich ecosystem of academic institutions, research talent, venture capital, and other biotech companies, fostering partnerships and innovation critical to its mission.

Values Reflected in HQ: The headquarters' design and operational ethos reflect Sarepta's core values: putting patients first, acting with urgency, driving innovation, upholding scientific integrity, and fostering a collaborative spirit.

Location:

Sarepta Therapeutics maintains a significant global presence to support its mission of delivering precision genetic medicines worldwide. Key functions supported globally include research and development collaborations, clinical trial operations across multiple continents, manufacturing and supply chain management, regulatory affairs in various jurisdictions, and commercial operations to ensure patient access to approved therapies. Their international headquarters in Dublin, Ireland, and offices in locations like Switzerland and Japan, complement their extensive U.S. operations, enabling them to serve patients with rare diseases on a global scale.

Street Address:

215 First Street

City:

Cambridge

State/Province:

MA

Country:

USA

Sarepta Therapeutics's Global Presence

Andover, MA, USA

Address: One Sarepta Way, Andover, MA 01810

Serves as a vital manufacturing and development hub in Massachusetts, leveraging the state's strong biomanufacturing infrastructure and talent pool.

Dublin, Ireland

Address: 70 Sir John Rogerson’s Quay, Dublin 2, Ireland

Manages and expands Sarepta's commercial presence and patient access initiatives outside the United States, navigating diverse regulatory and healthcare systems.

Columbus, OH, USA

Address: 371A West Fifth Avenue, Columbus, OH 43201

Acts as a primary center for gene therapy innovation and production, benefiting from Ohio's growing prominence in the gene therapy field and proximity to research partners.

Zug, Switzerland

Address: Dammstrasse 19, CH-6300 Zug, Switzerland

Provides a strategic base in continental Europe, facilitating business operations and market engagement in Switzerland and surrounding countries.

Buying Intent Signals for Sarepta Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Sarepta Therapeutics

As of April 2025, Sarepta Therapeutics' leadership includes:

Douglas S. Ingram - President and Chief Executive Officer
Louise Rodino-Klapac, Ph.D. - Executive Vice President, Head of R&D, and Chief Scientific Officer
Dallan Murray - Executive Vice President, Chief Commercial Officer
Ryan Brown - Executive Vice President, Chief Financial Officer
Ty Howton - Executive Vice President, Chief Operating Officer and General Counsel
Susie Lisa - Executive Vice President, Chief Business and Strategy Officer
Bo Cumbo - Executive Vice President, Chief People and Corporate Services Officer

Investors of Sarepta Therapeutics

Sarepta Therapeutics has been backed by several prominent investors over the years, including:

The Vanguard Group, Inc.
BlackRock, Inc.
FMR LLC (Fidelity Management & Research)
State Street Corporation
Capital World Investors

Executive New Hires/Exits in the Last 12 Months

Hire2
Exits1

Over the last 12 months (May 2023 - May 2024), Sarepta Therapeutics strengthened its executive leadership with strategic appointments, notably a new Chief Business and Strategy Officer and a new Chief Financial Officer, reflecting the company's ongoing growth and strategic evolution.

Departures

Ian Estepan, Ian Estepan departed as CFO, with Ryan Brown appointed as his successor.

New Appointments:

Susie Lisa, Susie Lisa joined Sarepta as EVP, Chief Business and Strategy Officer to spearhead strategic growth and business development efforts.
Ryan Brown, Ryan Brown was appointed as the new EVP, Chief Financial Officer, succeeding Ian Estepan.

Technology (Tech Stack) used by Sarepta Therapeutics

Discover the tools Sarepta Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Sarepta Therapeutics Email Formats and Examples

Sarepta Therapeutics primarily utilizes the email format combining the first initial and the full last name of the employee. For example, an employee named Jane Doe would likely have an email address such as 'jdoe@sarepta.com'. This is a common and professional email structure in the corporate and biotech sectors.

[first_initial][last]@sarepta.com

Format

jdoe@sarepta.com

Example

90%

Success rate

News and media

Sarepta Therapeutics Press Release (via GlobeNewswire)May 21, 2024

Sarepta Therapeutics Announces U.S. FDA Has Extended Review Period for the Biologics License Application for ELEVIDYS (delandistrogene moxeparvovec-rokl)

The U.S. Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) supplement for ELEVIDYS, Sarepta's gene therapy for Duchenne muscular dystrophy. The new PDUFA (Prescription Drug User Fee Act) target action date is June 21, 2024. The extension is to allow the FDA additional time to review information submitted by Sarepta, including data from the ENVISION study in older, non-ambulatory individuals with Duchenne....more

Sarepta Therapeutics Press Release (via GlobeNewswire)May 2, 2024

Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments

Sarepta reported total revenues of $413.5 million for the first quarter of 2024, a 65% increase compared to the same period in 2023. This growth was primarily driven by strong net product revenue from its approved PMO therapies (EXONDYS 51, VYONDYS 53, AMONDYS 45) and ELEVIDYS. The company also highlighted ongoing progress in its R&D pipeline and upcoming regulatory milestones....more

Sarepta Therapeutics Press Release (via GlobeNewswire)April 8, 2024

Sarepta Therapeutics Highlights Data From Its Duchenne Muscular Dystrophy Portfolio to be Presented at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Sarepta announced multiple presentations at the MDA 2024 conference, showcasing data across its Duchenne muscular dystrophy portfolio. This included long-term follow-up data for ELEVIDYS, updates on next-generation exon-skipping candidates like SRP-5051 (vesleteplirsen), and insights from its gene therapy programs, underscoring its commitment to advancing treatments for DMD....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Sarepta Therapeutics, are just a search away.